Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: A systematic review and meta-analysis

British Journal of Haematology

Volumn 141, Issue 6, 2008, Pages 882-890

  Mamtani, Manju ^a   Kulkarni, Hemant ^a,b  

^a Lata Medical Research Foundation   (India)

^b NONE   (United States)

Author keywords

Chelator; Iron; Meta analysis; Thalassaemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE;

ARTICLE; CLINICAL TRIAL; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON CHELATION; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SYSTEMATIC REVIEW; THALASSEMIA;

BLOOD TRANSFUSION; CHELATION THERAPY; HUMANS; IRON; IRON CHELATING AGENTS; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PUBLICATION BIAS; STROKE VOLUME; THALASSEMIA; VENTRICULAR FUNCTION, LEFT;

EID: 44249127965     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07122.x     Document Type: Article

References (53)

1. Aessopos, A., Farmakis, D., Hatziliami, A., Fragodimitri, C., Karabatsos, F., Joussef, J., Mitilineou, E., Diamanti-Kandaraki, E., Meletis, J. Karagiorga, M. (2004) Cardiac status in well-treated patients with thalassemia major. European Journal of Haematology, 73, 359 366.
2. Aessopos, A., Kati, M. Farmakis, D. (2007) Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica, 92, 658 665.
3. Aldouri, M.A., Wonke, B., Hoffbrand, A.V., Flynn, D.M., Ward, S.E., Agnew, J.E. Hilson, A.J. (1990) High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematologica, 84, 113 117.
4. Al-Quobaili, F.A. Abou Asali, I.E. (2004) Serum levels of lipids and lipoproteins in Syrian patients with beta-thalassemia major. Saudi Medical Journal, 25, 871 875.
5. Ayyub, M., Ali, W., Anwar, M., Waqar, A., Khan, M.N., Ijaz, A., Hussain, T. Hussain, S. (2005) Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan. Journal of Ayub Medical College, Abbottabad, 17, 12 15.
6. Borgna-Pignatti, C., Rugolotto, S., De Stefano, P., Zhao, H., Cappellini, M.D., Del Vecchio, G.C., Romeo, M.A., Forni, G.L., Gamberini, M.R., Ghilardi, R., Piga, A. Cnaan, A. (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica, 89, 1187 1193.
7. Borgna-Pignatti, C., Cappellini, M.D., De Stefano, P., Del Vecchio, G.C., Forni, G.L., Gamberini, M.R., Ghilardi, R., Piga, A., Romeo, M.A., Zhao, H. Cnaan, A. (2006) Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood, 107, 3733 3737.
8. Christoforidis, A., Haritandi, A., Tsatra, I., Tsitourides, I., Karyda, S. Athanassiou-Metaxa, M. (2007) Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens. European Journal of Haematology, 78, 52 57.
9. Chrysohoou, C., Panagiotakos, D.B., Pitsavos, C., Kosma, K., Barbetseas, J., Karagiorga, M., Ladis, I. Stefanadis, C. (2004) Distribution of serum lipids and lipoproteins in patients with beta thalassaemia major; an epidemiological study in young adults from Greece. Lipids in Health and Disease, 3, 3 On-line journal)
10. Daar, S. Pathare, A.V. (2006) Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Annals of Hematology, 85, 315 319.
11. Davis, B.A., O'Sullivan, C., Jarritt, P.H. Porter, J.B. (2004) Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood, 104, 263 269.
12. Egger, M., Davey Smith, G., Schneider, M. Minder, C. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629 634.
13. Farmakis, D., Deftereos, S., Giakoumis, A., Polymeropoulos, E. Aessopos, A. (2004) Rupture of chordae tendineae in patients with beta-thalassemia. European Journal of Haematology, 72, 296 298.
14. Fassos, F.F., Klein, J., Fernandes, D., Matsui, D., Olivieri, N.F. Koren, G. (1996) The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels. International Journal of Clinical Pharmacology and Therapeutics, 34, 288 292.
15. Freeman, A.P., Giles, R.W., Berdoukas, V.A., Talley, P.A. Murray, I.P. (1989) Sustained normalization of cardiac function by chelation therapy in thalassaemia major. Clinical and Laboratory Haematology, 11, 299 307.
16. Gaenzer, H., Marschang, P., Sturm, W., Neumayr, G., Vogel, W., Patsch, J. Weiss, G. (2002) Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. Journal of the American College of Cardiology, 40, 2189 2194.
17. Galia, M., Midiri, M., Bartolotta, V., Morabito, A., Rizzo, M., Mangiagli, A., Malizia, R., Borsellino, Z., Capra, M., D'Ascola, D.G., Magnano, C., Gerardi, C., Rigano, P. Maggio, A. (2003) Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study. Hemoglobin, 27, 63 76.
18. Hahalis, G., Alexopoulos, D., Kremastinos, D.T. Zoumbos, N.C. (2005) Heart failure in beta-thalassemia syndromes: a decade of progress. American Journal of Medicine, 118, 957 967.
19. Hershko, C., Link, G., Konijn, A.M. Cabantchik, Z.I. (2005) Objectives and mechanism of iron chelation therapy. Annals of the New York Academy of Sciences, 1054, 124 135.
20. Higgins, J.P. Thompson, S.G. (2002) Quantifying heterogeneity in a meta-analysis. Statistics in Medicine, 21, 1539 1558.
21. Hoffbrand, A.V. Wonke, B. (1997) Iron chelation therapy. Journal of Internal Medicine. Supplement, 740, 37 41.
22. Johnston, D.L., Rice, L., Vick, III., G.W., Hedrick, T.D. Rokey, R. (1989) Assessment of tissue iron overload by nuclear magnetic resonance imaging. American Journal of Medicine, 87, 40 47.
23. Karnon, J., Zeuner, D., Brown, J., Ades, A.E., Wonke, B. Modell, B. (1999) Lifetime treatment costs of beta-thalassaemia major. Clinical and Laboratory Haematology, 21, 377 385.
24. Kattamis, A., Ladis, V., Berdousi, H., Kelekis, N.L., Alexopoulou, E., Papasotiriou, I., Drakaki, K., Kaloumenou, I., Galani, A. Kattamis, C. (2006) Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells, Molecules, and Diseases, 36, 21 25.
25. Kolnagou, A. Kontoghiorghes, G.J. (2006) Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin, 30, 239 249.
26. Kolnagou, A., Economides, C., Eracleous, E. Kontoghiorghes, G.J. (2006) Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin, 30, 219 227.
27. Kontoghiorghes, G.J. (1992) Advances in oral iron chelation in man. International Journal of Hematology, 55, 27 38.
28. Kontoghiorghes, G.J. Kolnagou, A. (2005) Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators. Current Medicinal Chemistry, 12, 2695 2709.
29. Kontoghiorghes, G.J., Pattichi, K., Hadjigavriel, M. Kolnagou, A. (2000) Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfusion Science, 23, 211 223.
30. Kontoghiorghes, G.J., Neocleous, K. Kolnagou, A. (2003) Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Safety, 26, 553 584.
31. Kremastinos, D.T., Tsetsos, G.A., Tsiapras, D.P., Karavolias, G.K., Ladis, V.A. Kattamis, C.A. (2001) Heart failure in beta thalassemia: a 5-year follow-up study. American Journal of Medicine, 111, 349 354.
32. Kucukosmanoglu, O., Ozbarlas, N. Sasmaz, I. (2002) Complete heart block in thalassemia major: a case report. Turkish Journal of Pediatrics, 44, 261 262.
33. Lim, T.K., Burden, L., Janardhanan, R., Ping, C., Moon, J., Pennell, D. Senior, R. (2005) Improved accuracy of low-power contrast echocardiography for the assessment of left ventricular remodeling compared with unenhanced harmonic echocardiography after acute myocardial infarction: comparison with cardiovascular magnetic resonance imaging. Journal of the American Society of Echocardiography, 18, 1203 1207.
34. Maggio, A. (2007) Light and shadows in the iron chelation treatment of haematological diseases. British Journal of Haematology, 138, 407 421.
35. Maggio, A., D'Amico, G., Morabito, A., Capra, M., Ciaccio, C., Cianciulli, P., Di Gregorio, F., Garozzo, G., Malizia, R., Magnano, C., Mangiagli, A., Quarta, G., Rizzo, M., D'Ascola, D.G., Rizzo, A. Midiri, M. (2002) Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells, Molecules, and Diseases, 28, 196 208.
36. Mariotti, E., Agostini, A., Angelucci, E., Cesaroni, P., Lucarelli, G. Sgarbi, E. (1993) Cardiac study by dobutamine stress echocardiography in thalassemic patients. Bone Marrow Transplantation, 12 (Suppl. 1 14 15.
37. Meyers, D.G. (2000) The iron hypothesis:does iron play a role in atherosclerosis? Transfusion, 40, 1023 1029.
38. Modell, B., Khan, M. Darlison, M. (2000) Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet, 355, 2051 2052.
39. Neufeld, E.J. (2006) Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood, 107, 3436 3441.
40. Olivieri, N.F., Nathan, D.G., MacMillan, J.H., Wayne, A.S., Liu, P.P., McGee, A., Martin, M., Koren, G. Cohen, A.R. (1994) Survival in medically treated patients with homozygous beta-thalassemia. New England Journal of Medicine, 331, 574 578.
41. Olson, L.J., Edwards, W.D., McCall, J.T., Ilstrup, D.M. Gersh, B.J. (1987) Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. Journal of the American College of Cardiology, 10, 1239 1243.
42. Peng, C.T., Chow, K.C., Chen, J.H., Chiang, Y.P., Lin, T.Y. Tsai, C.H. (2003) Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan. European Journal of Haematology, 70, 392 397.
43. Pennell, D.J., Berdoukas, V., Karagiorga, M., Ladis, V., Piga, A., Aessopos, A., Gotsis, E.D., Tanner, M.A., Smith, G.C., Westwood, M.A., Wonke, B. Galanello, R. (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood, 107, 3738 3744.
44. Piga, A., Gaglioti, C., Fogliacco, E. Tricta, F. (2003) Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica, 88, 489 496.
45. Piga, A., Roggero, S., Vinciguerra, T., Sacchetti, L., Gallo, V. Longo, F. (2005) Deferiprone: new insight. Annals of the New York Academy of Sciences, 1054, 169 174.
46. Rosnow, R.L. Rosenthal, R. (1996) Computing contrasts, effect sizes, and counternulls on other people's published data: General procedures for research consumers. Psychological Methods, 1, 331 340.
47. Schwartz, K.A., Li, Z., Schwartz, D.E., Cooper, T.G. Braselton, W.E. (2002) Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction. Journal of Applied Physiology, 93, 746 751.
48. Sonakul, D., Thakerngpol, K. Pacharee, P. (1988) Cardiac pathology in 76 thalassemic patients. Birth Defects Original Article Series, 23, 177 191.
49. Storey, P., Thompson, A.A., Carqueville, C.L., Wood, J.C., de Freitas, R.A. Rigsby, C.K. (2007) R2* imaging of transfusional iron burden at 3T and comparison with 1.5T. Journal of Magnetic Resonance Imaging, 25, 540 547.
50. Tanner, M.A., Galanello, R., Dessi, G., Smith, G.C., Westwood, M.A., Agus, A., Roughton, M., Assomull, R., Nair, S.V., Walker, J.M. Pennell, D.J. (2007) A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation, 115, 1876 1884.
51. Weatherall, D.J. (1997) The thalassaemias. BMJ, 314, 1675 1678.
52. Westwood, M.A., Firmin, D.N., Gildo, M., Renzo, G., Stathis, G., Markissia, K., Vasili, B. Pennell, D.J. (2005) Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. The International Journal of Cardiovascular Imaging, 21, 531 538.
53. Wu, K.H., Chang, J.S., Su, B.H. Peng, C.T. (2004) Tricuspid regurgitation in patients with beta-thalassemia major. Annals of Hematology, 83, 779 783.